Novo Nordisk's top shareholder forces board overhaul, raising governance concerns | REUTERS

Key Concepts

• Novo Nordisk Foundation
• Board Overhaul
• Governance Concerns
• Voting Rights
• Dual Role (Chairman of Foundation and Company)
• Wegovy
• Eli Lilly
• Foundation Ownership Model
• Financial and Strategic Stability
• Scientific Research and Humanitarian Causes

Board Overhaul and Foundation Control

Novo Nordisk's top shareholder, the Novo Nordisk Foundation, successfully orchestrated an overhaul of the company's board on Friday. This significant move has granted the foundation unprecedented control over the drug maker, leading to protests from some investors who have raised governance concerns. The impetus for this reshuffle was the resignation of the board chair, Hel Galoon, last month, along with independent board members, who stepped down under pressure.

Foundation's Dominant Position and New Leadership

The Novo Nordisk Foundation already held a substantial 77% of the drug maker's voting rights. Following the board overhaul, the foundation's chairman, Lars Rebien Sørensen, has been appointed as the new chairman of Novo Nordisk. This appointment creates a dual role for Sørensen, a situation described as "never-before-seen" at the Danish drug maker, which has amplified concerns regarding the concentration of power. The foundation's dominant position was evident in the board vote, with the new board receiving over 90% approval.

Context: Wegovy Success and Recent Challenges

Novo Nordisk's ascent to become Europe's most valuable firm was largely driven by the successful 2021 launch of its blockbuster obesity drug, Wegovy. However, the company has faced challenges over the past year, including slowing sales and increased competition from rival Eli Lilly. This board shakeup occurs as Novo Nordisk is striving to stabilize its business following this turbulent period.

Novo Nordisk Foundation's Mandate and the Test of its Model

The Novo Nordisk Foundation is a non-profit entity established with the dual purpose of ensuring the financial and strategic stability of the Novo Group, while simultaneously advancing scientific research and humanitarian causes. The current situation, with Sørensen holding a dual role, is seen as a test of the foundation ownership model. The core question is whether this model, designed to provide stability, will indeed achieve that objective in practice.

Synthesis/Conclusion

The recent board overhaul at Novo Nordisk, driven by its majority shareholder, the Novo Nordisk Foundation, has consolidated significant power within the foundation and its chairman, Lars Rebien Sørensen. While the foundation's mandate is to ensure stability and support research, this unprecedented concentration of control has ignited governance debates among investors. The effectiveness of the foundation ownership model in navigating Novo Nordisk's current challenges, including increased competition and sales fluctuations, will be closely observed.